Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 11/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16639808 | 0.81 | PDGFRB (0.38) | DRD3CYP2D6DRD2KDM4EKDR | |
| SCHEMBL23488680 | 0.77 | NAMPT (0.31) | — | |
| SCHEMBL22652330 | 0.74 | NAMPT (0.40) | DRD3DRD2 | |
| SCHEMBL15242530 | 0.71 | DRD3 (0.40) | DRD3CYP2D6DRD2KDM4EKDR | |
| SCHEMBL25138304 | 0.71 | PDGFRB (0.46) | DRD3CYP2D6DRD2KDRPDGFRB | |
| SCHEMBL22867647 | 0.71 | ALDH1A1 (0.40) | CYP2D6KDM4EMEN1KMT2AHSP90AB1 | |
| SCHEMBL16644224 | 0.70 | HRH4 (0.47) | DRD3CYP2D6DRD2KDM4EKDR | |
| SCHEMBL26622982 | 0.67 | KDM4E (0.36) | KDM4ENUDT1HSP90AB1 | |
| SCHEMBL28342208 | 0.65 | KDR (0.37) | DRD3CYP2D6DRD2KDM4EKDR | |
| SCHEMBL21524570 | 0.64 | PTGS1 (0.37) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730889-B2 | Amido spirocyclic amide and sulfonamide derivatives | FORMA TM, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | Valo Health, LLC | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | STS, SQOR, SULT1E1 | DRD3 2447/4885CYP2D6 352/4885DRD2 2991/4885 |
| US-10730889-B2 | Amido spirocyclic amide and sulfonamide derivatives | STS, AADAC, SULT2A1 | DRD3 4161/4885CYP2D6 562/4885DRD2 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.